12 Most Promising Biotech Stocks According to Wall Street Analysts

5. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Analyst Upside: 55.69% 

The fifth stock on our list of the most promising stocks according to Wall Street analysts is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). It specializes in developing therapies for central nervous system disorders, focusing on neuropsychiatric symptoms. Its flagship product, NUPLAZID, is the only FDA-approved treatment for Parkinson’s disease psychosis, while its recently launched DAYBUE is the first approved treatment for Rett syndrome in the U.S. and Canada. With a strategic focus on unmet medical needs in neuroscience, the company has established itself as a leader in developing first-in-class therapies for complex disorders, setting it apart in the biotech industry.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) delivered strong financial results for Q4 and full-year 2024, showcasing significant revenue growth and strategic advancements. Total revenue reached $259.6 million in Q4 and $957.8 million for the year, driven by strong sales of its key products. NUPLAZID generated $162.9 million in Q4 and $609.4 million for the year, benefiting from increased unit sales and pricing. DAYBUE, the company’s novel treatment for Rett syndrome, contributed $96.7 million in Q4 and $348.4 million for the full year, which reflected rising market adoption.

The company’s profitability improved considerably, with a net income of $226.5 million in 2024, reversing a net loss of $61.3 million in 2023. This turnaround was fueled by higher revenues, cost management, and a one-time gain of $146.5 million from the sale of a Rare Pediatric Disease Priority Review Voucher. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended the year with $756 million in cash and investments, up from $438.9 million in 2023, providing financial flexibility for future growth.

Looking ahead, the corporation projects 2025 revenues between $1.03 and $1.095 billion, with expected NUPLAZID sales of $650–$690 million and DAYBUE sales of $380–$405 million. The company is also making strides in regulatory and clinical development, including a European regulatory submission for trofinetide and pipeline advancements in Prader-Willi syndrome, Alzheimer’s disease psychosis, and Lewy Body Dementia psychosis.